The new drug, Imraldi, marks the third European Commission approval for “biosimilar” versions from the joint venture, Samsung Bioepis, of drugs in a class known as TNF inhibitors.
Samsung, Biogen version of AbbVie’s Humira approved in Europe
Pharmaceuticals
iData Pharmaceutical News 09-01-2017: Company Acquisitions and FDA Approvals for Gene Therapy
CAR T-cell therapy approved to treat certain children and young adults with B-cell acute lymphoblastic leukemia – Oncodesign is expanding its service offering in immunology and infectious diseases
Sandoz Erelzi™ (etanercept) Receives Positive Reimbursement Recommendation from Common Drug Review for Treatment of Multiple Inflammatory Diseases
Sandoz, a Novartis division, recently announced that The Canadian Drug Expert Committee (CDEC) as part of the Common Drug Review (CDR) process has issued a positive drug reimbursement recommendation for Erelzi (etanercept). Health Canada granted Erelzi a Notice of Compliance in April 2017.
